HomeMOLN • SWX
add
Molecular Partners AG
Previous close
CHF 3.20
Day range
CHF 3.19 - CHF 3.36
Year range
CHF 3.04 - CHF 6.30
Market cap
122.20M CHF
Avg Volume
12.37K
P/E ratio
-
Dividend yield
-
Primary exchange
SWX
In the news
Financials
Income Statement
Revenue
Net income
| (CHF) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 1.03M | -61.72% |
Operating expense | 5.77M | -8.34% |
Net income | -19.78M | -13.48% |
Net profit margin | -1.92K | -196.46% |
Earnings per share | — | — |
EBITDA | -16.42M | -11.43% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (CHF) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 186.89M | -24.99% |
Total assets | 198.35M | -24.37% |
Total liabilities | 21.92M | -19.08% |
Total equity | 176.43M | — |
Shares outstanding | 32.85M | — |
Price to book | 0.60 | — |
Return on assets | -19.99% | — |
Return on capital | -21.89% | — |
Cash Flow
Net change in cash
| (CHF) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -19.78M | -13.48% |
Cash from operations | -15.99M | -12.07% |
Cash from investing | 19.46M | -45.80% |
Cash from financing | -298.00K | 0.00% |
Net change in cash | -1.09M | -105.97% |
Free cash flow | -9.36M | -2.88% |
About
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Founded
2004
Website
Employees
168
